BEVERLY, MA–(Marketwire – April 12, 2010) - Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, today announced that its CEO, George Evans, appeared on the radio program Stu Taylor on Business on Saturday evening. Mr. Evans discussed a range of issues regarding the Cellceutix portfolio of compounds. Kevetrin™, which is being developed to treat drug resistant cancers, and KM-391, which is being developed to treat autism spectrum disorder were prominently featured. Please visit the Cellceutix web site at www.cellceutix.com for a link to the program.
“This type of program is a great opportunity for companies like Cellceutix to get the word out about our important research efforts,” said Mr. Evans. ”We are going to keep looking for these chances to tell our story.”
In animal studies, Kevetrin has been found to significantly delay tumor growth in multi-drug resistant lung, breast and colon cancer cell lines. On April 20, Cellceutix will be presenting a poster of important new data on Kevetrin at the American Association for Cancer Research (AACR) in Washington, DC. More information about these studies and the AACR presentation is available on the Cellceutix web site atwww.cellceutix.com.
KM-391, Cellceutix’s novel compound in development for the treatment of autism, was shown to improve several key parameters in an animal model of autism. Given the urgent medical need in this area, the Company is working as rapidly as possible to move KM-391 toward human studies. The pharmaceutical industry is only recently gearing up to develop drugs that address the primary conditions of autism. At Cellceutix we hope to stay ahead of the curve on autism research.